AASLD 2025
This is the logo of the provider
AASLD 2025 7 - 10 November 2025

HbA1c-independent benefits of semaglutide on liver histology and non-invasive tests in participants with biopsy-defined MASH: insights from post-hoc analysis of the ESSENCE trial part 1

Authors :

A.J. Sanyal1; E. Bugianesi2; T. Arias-Loste3; L. Castera4; N.M. Eklöf5; W. Kim6; N. Krarup5; B. Ludvik7; P.N. Newsome8; V. Ratziu9; M.E. Rinella10; A. Trifan11; T.C. Vestergaard5; M. Roden12; ESSENCE study group
Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Download poster (.pdf)
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)